HCYTA-60K
MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A
Configurable Human Cytokine/Chemokine/Growth Factor 48-Plex Panel A
Synonym(s):
Human cytokine multiplex kit, Luminex® human cytokine immunoassay, Millipore human cytokine panel
Sign In to View Organizational & Contract Pricing.
About This Item
NACRES:
NA.84
UNSPSC Code:
12161503
Quality Level
species reactivity
human
packaging
pkg of 1 ea
manufacturer/tradename
Milliplex®
technique(s)
multiplexing: suitable
input
plasma
serum
cell culture supernatant(s)
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
General description
Cytokines, chemokines, and growth factors are key mediatorsof immune system functions capable of signaling through autocrine, paracrine,and endocrine mechanisms. Their pleiotropic immunomodulatory propertiesallow these biomolecules to react to diverse stimuli and regulate the immuneresponse, either promoting or inhibiting inflammation.
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 48 analytes in human serum, plasma, and cell culture supernatants.
Analytes included: sCD40L, EGF, Eotaxin/CCL11, FGF-2/FGF-basic, FLT-3L, Fractalkine/CX3CL1, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, M-CSF, MDC, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TGFα, TNFα, TNFβ/LTA, VEGF-A
Note: RANTES cannot be plexed with other cytokines in this panel due to a required 1:100 dilution of plasma/serum samples.
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Analytes included: sCD40L, EGF, Eotaxin/CCL11, FGF-2/FGF-basic, FLT-3L, Fractalkine/CX3CL1, G-CSF, GM-CSF, GROα, IFNα2, IFNγ, IL-1α, IL-1β, IL-1RA, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12 (p40), IL-12(p70), IL-13, IL-15, IL-17A/CTLA8, IL-17E/IL-25, IL-17F, IL-18, IL-22, IL-27, IP-10/CXCL10, MCP-1/CCL2, MCP-3/CCL7, M-CSF, MDC, MIG/CXCL9, MIP-1α/CCL3, MIP-1β/CCL4, PDGF-AA, PDGF-AB/BB, RANTES/CCL5, TGFα, TNFα, TNFβ/LTA, VEGF-A
Note: RANTES cannot be plexed with other cytokines in this panel due to a required 1:100 dilution of plasma/serum samples.
Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Features and Benefits
- 48-Plex Power, Simplified: One kit unlocks 48 biomarkers—replaces multiple ELISAs and slashes costs.
- More Than 20-Year Multiplexing Legacy: The original multiplex innovator—trusted by top pharma companies for critical assays.
- Cancer, Autoimmunity, & Beyond: Power research in immunotherapy, sepsis, Alzheimer’s, and Long COVID biomarker discovery.
- Intuitive Workflow: User-friendly protocols that require minimal training, allowing researchers to achieve publication-ready results without extensive background in multiplex assays.
- Configurable Assay Design: Configure your panel by selecting specific analytes based on your research needs, allowing for a tailored approach that maximizes relevance and impact.
- Robust Sample Compatibility: Verified for serum, plasma, PBMC supernatants, and cell/tissue lysates. Tested across normal and disease-state samples for broad applicability.
- Peer-Reviewed Credibility: Frequently cited in immunology and clinical research publications. Trusted by academic institutions, CROs, and pharma companies.
- Performance Highlights from Comparative Studies: MILLIPLEX® assays showed highest reproducibility among Luminex®-based kits in a head-to-head study and in disease profiling (e.g., ovarian cancer, sepsis), and MILLIPLEX® assays detected more significantly elevated analytes than competitors.
- Global Support & Documentation: Backed by extensive technical documentation, protocols, and customer support.
Legal Information
Luminex is a registered trademark of Luminex Corporation
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Disclaimer
For research use only. Not for use in diagnostic procedures.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Label License/Sticker for Assay Product:
By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Still not finding the right product?
Explore all of our products under MILLIPLEX® Human Cytokine/Chemokine/Growth Factor Panel A
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
Storage Class
10 - Combustible liquids
wgk
WGK 3
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Carl A Pierce et al.
JCI insight, 6(9) (2021-04-07)
BACKGROUNDCoronavirus disease 2019 (COVID-19) is more benign in children compared with adults for unknown reasons. This contrasts with other respiratory viruses where disease manifestations are often more severe in children. We hypothesize that a more robust early innate immune response
Carl A Pierce et al.
medRxiv : the preprint server for health sciences (2021-02-18)
COVID-19 is more benign in children compared to adults for unknown reasons. This contrasts with viruses such as influenza where disease manifestations are often more severe in children1. We hypothesized that a more robust early innate immune response to SARS-CoV-2
Yiwei Zhao et al.
Fertility and sterility, 115(4), 1044-1053 (2020-12-05)
To compare the changing peripheral levels of inflammation-related cytokine profile during a 9-day period after blastocyst transfer between women who did and did not conceive. Prospective, observational, and longitudinal study. University-affiliated hospital. Forty-seven women with infertility who were undergoing single
Global Trade Item Number
| SKU | GTIN |
|---|---|
| HCYTA-60K-13 | 04061841059332 |
| HCYTA-60K-33 | 04061841059530 |
| HCYTA-60K-07 | 04061841059271 |
| HCYTA-60K-17 | 04061841059370 |
| HCYTA-60K-47 | 04061841059677 |
| HCYTA-60K-08C | 04061841059769 |
| HCYTA-60K-18 | 04061841059387 |
| HCYTA-60K-18C | 04061841059868 |
| HCYTA-60K-12C | 04061841059806 |
| HCYTA-60K-28 | 04061841059486 |
| HCYTA-60K-23C | 04061841059912 |
| HCYTA-60K-38 | 04061841059585 |
| HCYTA-60K-38C | 04061841060062 |
| HCYTA-60K-26 | 04061841059462 |
| HCYTA-60K-48 | 04061841059684 |
| HCYTA-60K-42C | 04061841060109 |
| HCYTA-60K-36 | 04061841059561 |
| HCYTA-60K-09 | 04061841059295 |
| HCYTA-60K-30C | 04061841059981 |
| HCYTA-60K-19 | 04061841059394 |
| HCYTA-60K-12 | 04061841059325 |
| HCYTA-60K-15C | 04061841059837 |
| HCYTA-60K-04C | 04061841059721 |
| HCYTA-60K-32 | 04061841059523 |